IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

A Vogel; Gabriele Siegler; J Siebler; U Lindig; M Schultheiss; T Muller; H Simon; C Jockel; DW Mueller; SE Al-Batran; A Saborowski; EN De Toni

IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

A Vogel, Gabriele Siegler, J Siebler, U Lindig, M Schultheiss, T Muller, H Simon, C Jockel, DW Mueller, SE Al-Batran, A Saborowski, EN De Toni

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Abstract (Journal) › peer-review

11 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	40
Issue number	16
Publication status	Published - 2022

Cite this

Vogel, A., Siegler, G., Siebler, J., Lindig, U., Schultheiss, M., Muller, T., Simon, H., Jockel, C., Mueller, DW., Al-Batran, SE., Saborowski, A., & De Toni, EN. (2022). IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC). JOURNAL OF CLINICAL ONCOLOGY , 40(16).

Vogel, A ; Siegler, Gabriele ; Siebler, J et al. / IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC). In: JOURNAL OF CLINICAL ONCOLOGY 2022 ; Vol. 40, No. 16.

@article{f2c99957d50f40eaa6027a962a7989e8,

title = "IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).",

author = "A Vogel and Gabriele Siegler and J Siebler and U Lindig and M Schultheiss and T Muller and H Simon and C Jockel and DW Mueller and SE Al-Batran and A Saborowski and {De Toni}, EN",

year = "2022",

language = "English",

volume = "40",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "16",

}

Vogel, A, Siegler, G, Siebler, J, Lindig, U, Schultheiss, M, Muller, T, Simon, H, Jockel, C, Mueller, DW, Al-Batran, SE, Saborowski, A & De Toni, EN 2022, 'IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).', JOURNAL OF CLINICAL ONCOLOGY , vol. 40, no. 16.

IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC). / Vogel, A; Siegler, Gabriele; Siebler, J et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 40, No. 16, 2022.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

AU - Vogel, A

AU - Siegler, Gabriele

AU - Siebler, J

AU - Lindig, U

AU - Schultheiss, M

AU - Muller, T

AU - Simon, H

AU - Jockel, C

AU - Mueller, DW

AU - Al-Batran, SE

AU - Saborowski, A

AU - De Toni, EN

PY - 2022

Y1 - 2022

M3 - Abstract (Journal)

SN - 0732-183X

VL - 40

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 16

ER -

Vogel A, Siegler G, Siebler J, Lindig U, Schultheiss M, Muller T et al. IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC). JOURNAL OF CLINICAL ONCOLOGY . 2022;40(16).